Omar Abudayyeh, Ph.D., is a McGovern Institute Fellow at the Massachusetts Institute of Technology where he leads a lab on exploring microbial diversity for new biotechnological tools related to genome editing and gene delivery. He previously was at Harvard Medical School and the Harvard-MIT Health Sciences and Technology program as a graduate student. He completed his doctoral work in Feng Zhang’s lab at the Broad Institute of MIT and Harvard, where his research centered on novel CRISPR enzymes for applications in genome editing, therapeutics, and diagnostics. Dr. Abudayyeh’s work focused on uncovering novel CRISPR enzymes beyond Cas9 for biotechnological applications. He co-led the discovery and characterization of multiple landmark pieces of work, including the characterization of Cpf1 for novel genome editing applications and the first single-protein RNA-guided RNA-targeting enzyme C2c2/Cas13. His follow-up work on C2c2/Cas13 biology led to the development of SHERLOCK technology, and a new set of tools for precise editing of transcripts and visualizing them in mammalian cells with potential for RNA therapeutics. In recognition of his technology developments, Dr. Abudayyeh was recognized as 2018 Forbes 30 under 30 in Science and Health Care and Business Insider 30 under 30. Dr. Abudayyeh graduated from MIT in 2012 with a B.S. in mechanical engineering and biological engineering, where he was a Henry Ford II Scholar and a Barry M. Goldwater Scholar.